The mechanisms underlying abnormal granuloma formation in patients with sarcoidosis are complex and remain poorly understood. A novel in vitro human granuloma model was used to determine the molecular mechanisms of granuloma genesis in patients with sarcoidosis in response to putative disease-causing mycobacterial antigens. Peripheral blood mononuclear cells (PBMCs) from patients with active sarcoidosis and from normal, disease-free control subjects were incubated for 7 days with purified protein derivative-coated polystyrene beads. Molecular responses, as reflected by differential expression of genes, extracellular cytokine patterns, and cell surface receptor expression, were analyzed. Unbiased systems biology approaches were used to identify signaling pathways engaged during granuloma formation. Model findings were compared with human lung and mediastinal lymph node gene expression profiles. Compared with identically treated PBMCs of control subjects (n = 5), purified protein derivative-treated sarcoidosis PBMCs (n = 6) were distinguished by the formation of cellular aggregates resembling granulomas. Ingenuity Pathway Analysis of differential expression gene patterns identified molecular pathways that are primarily regulated by IL-13, which promotes alternatively activated (M2) macrophage polarization. M2 polarization was further demonstrated by immunohistochemistry performed on the in vitro sarcoidosis granuloma-like structures. IL-13-regulated gene pathways were confirmed in human sarcoidosis lung and mediastinal lymph node tissues. The in vitro human sarcoidosis granuloma model provides novel insights into early granuloma formation, particularly IL-13 regulation of molecular networks that regulate M2 macrophage polarization. M2 macrophages are predisposed to aggregation and multinucleated giant cell formation, which are characteristic features of sarcoidosis granulomas.
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Keywords: AmpliSeq; macrophage; peripheral blood mononuclear cells; purified protein derivative Mechanisms of early granuloma formation during sarcoidosis are currently unknown. Existing paradigms focus on classically activated (M1) macrophages expressing human leukocyte antigen (HLA) class II molecules that promote T-helper cell type 1 (Th1) immune cell activation in response to common antigens (e.g., Mycobacterium tuberculosis [M.tb.]), leading to a type 2 IFN-mediated proinflammatory granulomatous response (1) . However, sarcoidosis tissue macrophages express markers such as CD163 (2) and matrix metalloprotease (MMP)-12 (3), indicating the presence of an alternatively activated, immune-suppressive (M2) phenotype in diseased sarcoidosis tissues. Indeed, the fusion of macrophages to form multinucleated giant cells, a histopathological feature of sarcoidosis granulomas, is mediated, at least in part, by M2 macrophages (4).
We have recently developed a human in vitro model of granuloma formation wherein peripheral blood mononuclear cells (PBMCs) of patients with sarcoidosis who are naive to M.tb. readily form cell aggregates resembling granulomas when stimulated by purified protein derivative (PPD)-coated beads (5) . In vitro granuloma formation by sarcoidosis PBMCs was shown to be significantly greater than that of healthy, M.tb.-naive controls, and proinflammatory T-cell responses were paradoxically reduced (5) . These and other features of the in vitro model routinely recapitulate in vivo features of the disease (5) . Using the in vitro human granuloma model, we sought to determine the molecular mechanisms associated with enhanced granuloma formation in patients with active pulmonary sarcoidosis using genome-wide gene expression analysis coupled with a systems biology approach.
Methods
See the data supplement for additional methodological details.
Study Subjects
This study was approved by The Ohio State University Institutional Review Board (2014H0380) and is registered with www.clinicaltrials.gov (NCT01857401). Sarcoidosis inclusion criteria were based on 
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biopsy-proven noncaseating granulomatous tissue inflammation in the absence of other likely causes as per established criteria (6) with radiographic evidence of active (nonfibrotic) lung disease and negative screening for M.tb. (PPD skin test and/or IFN-g release assay negative result using the QuantiFERON test; QIAGEN). The study subjects were not active smokers and were not actively treated with immune suppressants. Blood samples were obtained from two study groups: 1) patients with active pulmonary sarcoidosis (n = 6) and 2) matching disease-free, PPD skin test-negative, and/or QuantiFERONnegative control subjects (n = 5). In addition, granulomatous tissues (lung [n = 6] and mediastinal lymph node [n = 8]) obtained from additional unrelated groups of sarcoid patients and matching diseasefree control subjects (n = 6 and n = 5, respectively) who met the criteria mentioned above were also processed and analyzed, as detailed below and in the data supplement, to determine the gene expression differences between the groups. The demographic features of all study subjects in each group and the diverse clinical characteristics of the patients with sarcoidosis in the present in vitro granuloma study and from whom granulomatous tissues were obtained are summarized in Table 1 and in Tables E1 and  E2 in the data supplement, respectively.
PPD-coated Bead Preparation
Fluoresbrite carboxylated microspheres (bright blue fluorescence, 1.0 mm; Polysciences) were either covalently coupled to tuberculin PPD via the carbodiimide method (further described in the data supplement) or washed and resuspended in PBS, then diluted with RPMI media and added at a concentration of 50:1 relative to the number of monocytes/macrophages present in each sample.
Human PBMC Isolation and Culture Conditions
PBMCs were isolated from whole-blood samples using Ficoll-Paque PLUS (GE Healthcare Life Sciences) (5) as detailed further in the data supplement. PBMC preparations (2 3 10 6 cells/ml) were then cultured in RPMI 1640 medium containing 10% human AB serum and either uncoated (PBS-washed) or PPD-coated beads for 7 days with or without leflunomide (50 mM) before treatment.
Extracellular Cytokine Analysis
Human PBMC-cleared supernatants were analyzed 7 days after treatment for IFN-g, IL-10, and IL-13 by ELISA according to the manufacturer's recommendations.
Granuloma Gene Expression Analysis
Granuloma cells were harvested into TRIzol reagent (Thermo Fisher Scientific), and total RNA was purified of DNA contamination using the SpinSmart RNA purification kit (Thomas Scientific). RNA libraries were prepared using the Ion Torrent AmpliSeq Transcriptome Human Gene Expression Kit (Thermo Fisher Scientific) from 10 ng of RNA. Quantitative gene expression analysis was performed using the AmpliSeq platform as previously described (5) and as specified further in the data supplement.
Gene expression data were normalized and postalignment statistical analyses performed using DESeq2 (7), and statistical comparisons of gene expression were determined from the normalized read counts based on a 10% false discovery rate (DESeq2-adjusted P < 0.05) and a fold change cutoff of 2 for each comparison. Total RNA was isolated from frozen lung or mediastinal lymph node tissues using TRIzol reagent according to the manufacturer's protocol and as described further in the data supplement. The RNA was purified using the RNeasy Mini Kit (QIAGEN), and the integrity of the purified total RNA samples was assessed qualitatively on an Agilent 2100 Bioanalyzer (Agilent Technologies). Samples were then processed using high-density oligonucleotide Human Genome U133 Plus 2 arrays (Affymetrix), which analyze the expression levels of over 47,000 transcripts and variants, including 38,500 well-characterized human genes.
Gene Network Analysis
Functional and network analyses of gene expression data derived from the AmpliSeq results and the Affymetrix Human Genome U133 Plus 2 chips were performed independently using Ingenuity Pathways Analysis (IPA) software (Ingenuity Systems Inc.; www.ingenuity.com).
Results

In Vitro Cell Aggregation Resembling Granulomas
Incubation of PBMCs from patients with sarcoidosis (n = 6) or control subjects (n = 5) with uncoated beads for 7 days yielded minimal cell aggregation. By contrast, treatment of sarcoidosis PBMCs with PPD-coated beads elicited the formation of 
Gene Expression Profile of In Vitro Sarcoidosis Granulomas
Comparison of RNA expression measured by AmpliSeq in sarcoidosis PBMCs incubated for 7 days with PPD-coated beads with identically treated control PBMCs yielded 1,274 significantly differentially expressed genes (unpaired group comparison; .2-fold; P , 0.05 by DESeq2 [7] ). In contrast, no differentially expressed genes were detectable when we compared sarcoidosis with controls after treatment with uncoated beads for 7 days, indicating that the observed gene expression changes were related specifically to PPD. Figure 2 presents mean normalized counts plotted against average fold change (MvA plot) and volcano plots of the gene expression data, demonstrating distinct gene expression characteristics under these conditions. Using a gene network analysis that is based on known molecular interactions (IPA), it is feasible to identify molecular patterns that provide insight into disease mechanisms. The results of this upstream analysis designed to identify primary regulators, based on statistical probability, responsible for the gene expression changes observed in the data set (8) identified IL-13 as the cytokine most strongly regulating the differential expression of genes in the sarcoidosis group (Figure 3) . At a higher level of analysis based on the IPA tool, which shows the strongest interactions among differentially expressed genes, an interactive network of molecules coregulated by IL-13 and IL-1B was identified ( Figure 4A ). Using the same IPA network analysis, we also identified IL-13 coregulated networks in independently examined human sarcoidosis lung and lymph node tissues (Figures 4B and 4C, respectively).
Alternatively Activated (M2) Macrophage Polarization in Sarcoidosis Granulomas
The macrophage gene expression profile of PBMCs from patients with sarcoidosis 7 days after PPD treatment was compared The output type "MvA" plots of normalized gene expression data wherein each point represents a gene, with the y-axis representing a log(base 2) fold change in expression after 7-day treatment with PPD-coated beads of PBMCs derived from patients with sarcoidosis compared with identically treated PBMCs from normal, healthy control subjects. The x-axis is the log average of the gene expression level. All genes with an adjusted P value of 0.05 (representing a 5% false discovery rate) and at least a twofold change (highlighted by the two horizontal gray lines) in the magnitude of gene expression between patients with sarcoidosis and control subjects are shaded red. The blue line represents smoothed local mean expression (fitted using a generalized additive model) with the surrounding 95% confidence interval shaded light blue. The dashed gray contour lines represent a two-dimensional density estimation. Genes that are most differentially expressed in response to PPD-coated beads in patients with sarcoidosis compared with control subjects are highlighted in the top part of the MvA plot, whereas those genes most differentially expressed in control subjects compared with patients with sarcoidosis are at the bottom. (The top five most differentially expressed genes in each case are labeled.) (B) Volcano plots of the same data wherein the y-axis corresponds to transcripts with high statistical significance (2log 10 of P value) and the x-axis corresponds to fold change of gene expression (log base 2) were also generated from the same data set. Labeled transcripts on the upper left side of the plot have strong statistical significance with relatively low expression after treatment of PBMCs with PPD-coated beads of sarcoidosis versus controls. Transcripts on the upper right are more highly expressed with strong statistical significance between sarcoidosis and controls after PPD treatment. The dotted line corresponds to a P value cutoff of 0.05, and genes failing to meet this cutoff are shaded gray. Data were generated from all 11 experiments (six sarcoidosis and five controls).
with that of identically treated PBMCs of disease-free control subjects, reflecting a strong polarization toward putative M2 molecules, as reflected by patterns of highly expressed transcripts (Table 2) and reduced expression of genes conforming to the M1 phenotype (SLC7A5, IL2RA, GZMA, FAS) (not shown). Among these putative M2 molecules, CD163 gene expression (and its receptor) was particularly elevated in sarcoidosis granulomas after PPD-coated bead treatment relative to treatment-matched controls, and CD163 is regulated by M2 cytokines IL-13 (9) and IL-10 (10, 11). Higher relative CD163 protein expression was confirmed in sarcoidosis granulomas by immunohistochemistry compared with matching controls after PPD-coated bead treatment ( Figure 5 and in a 3D video view of the granuloma shown in Video 2). Macrophage M2 polarization via IL-13 activation of STAT6 (signal transducer and activator of transcription 6) was further demonstrated by significantly diminished granuloma formation when PPD-stimulated sarcoid PBMCs were pretreated with the STAT6 inhibitor leflunomide (Figure 6 ). Insight into the mechanisms by which M2 macrophages aggregate is further provided by the observed increase in CD11 and CD18 expression in PPDtreated PBMCs from sarcoidosis (12) . CD11b and CD18 combine to form the heterodimeric protein Mac-1 (macrophage-1 antigen), which has implications for macrophage aggregation, as discussed below. Figure 3 . Pathway analysis predicts IL-13 as an important upstream regulator of the observed gene expression changes. Predictions are based on two statistical measures reflecting data set genes known to be regulated by each specific cytokine or transcription factor (overlap P value) and activation (z-score) based on the known direction by which the upstream regulator is known to influence the gene target (inhibition vs. activation). Details of the statistical methods are provided by Ingenuity Systems (8) . Applying this statistical approach to the differential gene expression pattern of PBMCs of patients with sarcoidosis compared with healthy control subjects determined 7 days after treatment with PPD-coated beads yielded the above IL-13-regulated network. Data were generated from all 11 experiments (six sarcoidosis and five controls).
Leukocyte Immunoglobulin-Like Receptor Family B Molecule expression
All five members of the LILRB (leukocyte immunoglobulin-like receptor family B) family (LILRB1-5) were overexpressed 7 days after PPD treatment in sarcoidosis PBMCs relative to controls (Table 3) . Likewise, members of the LILRB family were overexpressed in established granulomas derived from diseased human sarcoidosis tissues. LILRB molecules have important implications for regulating M2/Th2 immune responses (discussed below). ) compared with disease-free control lung tissues (n = 6) using a cutoff of greater than or equal to twofold change (P , 0.05) identified IL-13 as a putative mediator of the granulomatous response, including regulation of metalloproteases MMP-12 and ADAMDEC1, the expression of which correlated significantly with pulmonary sarcoidosis disease severity (3).
ORIGINAL RESEARCH M1/M2 Cytokine Ratios during In Vitro
Human Granuloma Formation IFN-g promotes M1 polarization, whereas IL-13 and IL-10 promote M2 polarization (9-11, 13). IFN-g/IL-10 and IFN-g/IL-13 differential expression ratios were lower in sarcoidosis compared with controls, consistent with a relative M2 cytokine balance (Table 4) .
Discussion
Mechanisms of early granuloma formation in sarcoidosis are enigmatic and complex, evolving from the dynamic interaction of multiple immune cell types, the features of which are changing over time. Complex genetic factors that predispose to sarcoidosis in humans, not readily modeled in animals, are yet another variable that needs to be considered. Human tissue samples are of limited value for understanding early granuloma genesis in that they provide a static image of well-formed, established granulomas of unknown age and presumably representing a chronic maintenance phase of granuloma. Nonetheless, certain molecular features, such as increased MMP12 (an IL-13-regulated molecule [14] ) expression, are observed at all stages of experimental in vivo granuloma formation (15) , implying common core mechanisms throughout all stages of granuloma formation that are regulated by IL-13. Thus, the in vitro model of granuloma formation employed in the present study, coupled with an unsupervised genomic systems biology approach, allowed us to consider novel mechanisms contributing to early granuloma formation in sarcoidosis. In contrast to currently held paradigms implicating Th1 and M1 (proinflammatory) mechanisms (16), our findings demonstrate strong M2 polarization during early granuloma formation in patients with a chronically active pulmonary sarcoidosis phenotype, and they further incriminate IL-13 as a proximal regulator of these events.
Alternatively Activated (M2) Macrophages and Sarcoidosis
The observed M2 polarization of macrophages in patients with sarcoidosis provides new perspective on previously documented features of macrophages in patients with active sarcoidosis. A distinguishing feature of alveolar macrophages from patients with sarcoidosis is enhanced antigen presentation (17), which has been interpreted to represent M1 macrophage polarization, such as is reflected by increased HLA-DMA (Table 2) . However, M2 signatures, such as CD163 (2) and MMP-12 (5), were previously observed in human sarcoidosis tissue granulomas, and their expression correlated with pulmonary disease severity (3, 18) . Moreover, M2 macrophage polarization, as reflected by increased CD163 expression, is associated with enhanced antigen presentation within a select subset of regulatory T cells, leading to lower concentrations of IFN-g and higher concentrations of IL-10 upon stimulation (19) (lower IFN-g/IL-10 ratio [ Table 4 ]), as demonstrated in this study. Another interesting property of CD163-expressing cells is a paradoxical high-level release of both IL-4 (promoting Th2 immune responses) and TNF-a (an M1 marker) (20) , and high concentrations of TNF-a were previously reported in this model (5) . The simultaneous expression of M2 and M1 features speaks to the plasticity of macrophages that is commonly observed in the context of human disease (21) . Nonetheless, the prevailing molecular signature of the in vitro human granuloma model is toward M2 macrophage polarization ( Table 2 ).
The molecular mechanisms regulating M2 macrophage polarization are well established, including IL-4-and IL-13-mediated activation of STAT6, with subsequent induction of numerous downstream mediators. The present study provides novel insights into M2 polarization mechanisms during the early phases of granuloma formation in the context of sarcoidosis. Figures 3 and 4A implicate a central role for IL-13 as a proximal upstream regulator of molecular events during the early evolution of sarcoidosis granulomas. This finding is supported by increased IL-13 expression in the BAL fluid cells and PBMCs of humans with active pulmonary sarcoidosis (22) , and as reflected by the central role of IL-13 in molecular networks derived from genomic analyses of human sarcoidosis tissues ( Figures 4B and 4C) . Indeed, in sarcoidosis lung tissues, IL-13 is predicted to regulate the expression of metalloproteases MMP-12 and ADAMDEC1 (ADAM-like decysin 1) (Figure 4C ), the expression of which significantly correlates with pulmonary sarcoidosis disease severity (3). The central role of the IL-13/STAT6 signaling pathway in the genesis of sarcoidosis granulomas was supported by the inhibitory effects of leflunomide, a potent STAT6 inhibitor (23), which is effective for the treatment of sarcoidosis ( Figure 6) (24, 25) .
Molecular Mechanisms of Macrophage Aggregation in Sarcoidosis
M2 macrophage polarization favors macrophage aggregation and multinucleated giant cell formation, which are histological hallmarks of sarcoidosis granulomas. In this regard, circulating leukocytes of patients with sarcoidosis express higher concentrations of CD11b and CD18 (12) , and the CD11b/CD18 heterodimer (Mac-1) promotes macrophage aggregation (26) and is incriminated in the context of granulomatous infections (27) . Mac-1 is further shown to promote IL-13-mediated M2 macrophage polarization (28) . Thus, we posit that CD11b and CD18, which are highly expressed in the in vitro sarcoidosis granuloma model (3.1-and 2.5-fold in sarcoidosis compared with controls [P , 0.05], respectively) and in diseased sarcoidosis lymph nodes (3.1-and 3.9-fold in sarcoidosis relative to controls [P , 0.05], respectively), contribute to early M2 polarization and to immune cell aggregation in the context of sarcoidosis.
Considering the Role of LILRB Family Molecules in Early Granuloma Formation
LILRB molecules promote M2 and Th2 polarization (29) . The LILRB family members are expressed on various immune cells, including dendritic cells, monocytes, and lymphocytes (T cells, natural killer cells, and B cells), generally inhibiting the proinflammatory interactions among these cells and with proinflammatory S100 proteins (30) . LILRB molecules are important regulators of granulomatous responses, such as leprosy (31) , by reducing M1/Th1 (IFN-g-induced) immunity (30) . In the present study, all five LILRB family member genes (i.e., LILRB1-5) were highly expressed during early sarcoidosis granulomas (Table 3 ). The implications of the LILRB family in the context of sarcoidosis will require further investigation; however, we posit that LILRB molecules contribute to M2 polarization as well as T-cell anergy, as reflected by a regulatory T-cell cytokine profile (i.e., comparatively lower IFN-g/IL-13 [ Table 4 ]). Thus, LILRB expression could explain suppression of inflammatory T-cell responses (relative T-cell anergy) compared with disease-free controls observed in the in vitro model and as documented in vivo in the context of active pulmonary 
Clinical Implications of This Study
The insights provided in this paper have important clinical implications, including therapeutic ones. Doxycycline, a potent inhibitor of M2 macrophage polarization (34) , and leflunomide, an inhibitor of STAT6 and related M2 gene expression (23) , are effective treatments for sarcoidosis (25, 35) . Given the diverse functional properties of M2 macrophages, including the "paradoxical" promotion of granuloma formation and suppression of Th1-mediated inflammation, a nuanced targeting of these pathways may be effective in selective suppression of granuloma formation without unleashing proinflammatory T-cell responses.
Unanswered Questions and Study Limitations
The factors influencing the balance between M1 and M2 macrophage polarization are complex and dynamic. For instance, during the evolution of M.tb.-induced granuloma formation, a predominant M1 immune response is observed in the early stages of infection, giving way to an M2-predominant response in association with granuloma formation within 9 days (36 (37) . Additional immune cells are recruited while others (e.g., T cells) proliferate to further amplify the inflammatory response. Moreover, direct activation of circulating immune cells is sufficient for recapitulating important features of diseased tissue (e.g., Figures 4B and 4C ). Most importantly, PBMCs of patients with active sarcoidosis harbor the complex genetic features that predispose to the disease. Thus, the model appears to be a reliable surrogate for human disease.
Conclusions
The in vitro human granuloma model provides novel insights into early granuloma formation in the context of sarcoidosis. Using an unbiased analysis of the molecular and genetic features of sarcoidosis granulomas, we show that ORIGINAL RESEARCH macrophages are strongly polarized toward an M2 phenotype, which favors macrophage aggregation. Furthermore, the same mechanisms promoting M2 polarization can promote inhibitory T-cell expression, possibly involving the LILRB family, thus explaining the "immune paradox" of sarcoidosis wherein exuberant granuloma formation occurs in association with T-cell anergy (31, 38) . This study further implicates inhibitors of M2 polarization as a potential approach to mitigate disease progression in patients with sarcoidosis with progressive disease. n Author disclosures are available with the text of this article at www.atsjournals.org.
